Accessibility Menu
Fennec Pharmaceuticals logo

Fennec Pharmaceuticals(NASDAQ) FENC

Market Cap$402.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)-90%
5 Year+70%
1 Year+43%
1 Month+13%
$10.95
-5.40%
-0.63Today
After hours$10.91-$0.04 (-0.37%)
Fennec Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 11.582026-08-07
Fennec Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+20.95%USD 9.572026-07-31
1 month+12.93%USD 10.252026-07-08
3 month+67.03%USD 6.932026-05-08
Year to date+50.32%USD 7.702025-12-31
1 year+43.43%USD 8.072025-08-07
3 year+42.02%USD 8.152023-08-08
5 year+69.97%USD 6.812021-08-06
Since inception-89.79%USD 113.402004-11-12

Fennec Pharmaceuticals Financials at a Glance

Market Cap

$402.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$51.00M

Net Income (TTM)

-$8.38M

EPS (TTM)

-$0.30

P/E Ratio

-39.08

Dividend

$0.00

Beta (Volatility)

0.67 (Low)

Price

$10.95

Volume

311,858

Open

$11.42

Previous Close

$10.94

Daily Range

$10.76 - $11.58

52-Week Range

$5.65 - $11.66

Estimated Earnings Date

Aug 13, 2026

FENC News

featured-earnings-leadership-highlights.png

Fennec Q2 Sales Jump 33 Percent

Motley Fool Markets TeamAug 14, 2025

FENC: Motley Fool Moneyball Superscore

60

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Fennec Pharmaceuticals

Fennec makes medicine that prevents hearing loss in kids with cancer. This drug protects children from side effects of chemotherapy treatments. The company helps pediatric patients at many major cancer hospitals.

Protecting Young Ears

  • PEDMARK: Injectable medicine used during chemotherapy to reduce permanent hearing loss in children; marketed as PEDMARQSI in Europe.
  • Fennec HEARS: Support program offering financial aid and insurance guidance for families; ensures patient access to specialized oncology treatments.

Growing the Global Reach

  • Partnered with Norgine in March 2024 to commercialize its lead drug in Europe, Australia, and New Zealand.
  • Signed a distribution agreement with Inpharmus in 2025 covering Turkey and the Gulf region.
  • Settled a patent lawsuit with Cipla in March 2026 to prevent generic competition until September 2033.
  • Announced positive results from a Japanese clinical trial in December 2025 to support international registration.

What Makes Fennec Different?

Fennec holds the only FDA-approved therapy for preventing chemotherapy-related hearing loss in pediatric patients. The company maintains its market position through orphan drug exclusivity and patents lasting until 2039.

The Financial Scorecard

  • Revenue reached $14 million in Q4 2025, up 76.5% from Q4 2024.
  • Gross profit hit $12.2 million in Q4 2025, up 68.1% year-over-year.
  • Operating loss reached $3.1 million in Q4 2025, worsening by 227.9% from Q4 2024.
  • Net loss hit $5.2 million in Q4 2025, worsening by 163.1% year-over-year.

Bottom Line

Fennec has transitioned from a research firm to a commercial company with a unique pediatric oncology product. Its recent licensing deals and patent settlements establish a framework for long-term international distribution.

AI Generated • May 14, 2026

Industry

Biotechnology

Sector

Health Care

Employees

35

CEO

Jeffrey S Hackman

Website

www.fennecpharma.com

Headquarters

Research Triangle Park, NC 27709, US

FENC Financials

Key Financial Metrics (TTM)

Gross Margin

92.23%

Operating Margin

-11.04%

Net Income Margin

-16.42%

Return on Equity

-54.75%

Return on Capital

-18.10%

Return on Assets

-11.66%

Earnings Yield

-2.56%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$402.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

34.74M

Volume

311.86K

Avg. Volume

269.15K

Financials (TTM)

Gross Profit

$47.04M

Operating Income

-$5.63M

EBITDA

-$6.67M

Operating Cash Flow

-$5.78M

Capital Expenditure

$0.00

Free Cash Flow

-$5.78M

Cash & ST Invst.

$40.18M

Total Debt

$0.00

Fennec Pharmaceuticals Performance Analysis

Fennec Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,535,000N/A
20232023-12-31USD 21,252,0001284.5%
20242024-12-31USD 47,538,000123.7%
20252025-12-31USD 44,642,000-6.1%
Fennec Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3010.3%
Q32025-09-3029.1%
Q42025-12-3110.6%
Q12026-03-319.7%
Fennec Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.9035.3%
20232023-12-31USD -0.60-33.1%
20242024-12-31USD -0.02-97.4%
20252025-12-31USD -0.342030.6%
Fennec Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-184.4%
Q32025-09-3080.9%
Q42025-12-31-642.4%
Q12026-03-31103.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$15.11M

+72.6%

Gross Profit

$14.54M

+73.5%

Gross Margin

96.23%

N/A

Market Cap

$402.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$11.49M

N/A

Employees

35

N/A

Net Income

$201.00K

+117.3%

EBITDA

$234.00K

+142.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$40.18M

+77.2%

Total Debt

$0.00

-100.0%

Accounts Receivable

$18.76M

+21.5%

Inventory

$1.86M

+32.2%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

N/A

Return on Assets

-11.66%

N/A

Return on Invested Capital

-9.05%

N/A

Free Cash Flow

$2.38M

+155.1%

Operating Cash Flow

$2.38M

+155.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ENTAEnanta Pharmaceuticals, Inc.
$13.81+0.29%
PRLDPrelude Therapeutics Incorporated
$4.83-1.43%
OBIOOrchestra BioMed Holdings, Inc.
$4.46+5.19%
RNACCartesian Therapeutics, Inc.
$8.76-1.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$138.74+0.04%
ACHRArcher Aviation
$6.26+0.12%
NVDANvidia
$217.55-0.03%
INTCIntel
$97.52-0.04%

Questions About FENC

What is the current price of Fennec Pharmaceuticals?

Fennec Pharmaceuticals is trading at $10.94 per share.

What is the 52-week range for Fennec Pharmaceuticals?

Over the past 52 weeks, Fennec Pharmaceuticals has traded between $5.65 and $11.66.

How much debt does Fennec Pharmaceuticals have?

As of the most recent reporting period, Fennec Pharmaceuticals reported total debt of $0.00.

How much cash does Fennec Pharmaceuticals have on hand?

Fennec Pharmaceuticals reported $40.18M in cash and cash equivalents in its most recent financial results.

What is Fennec Pharmaceuticals’s dividend yield?

Fennec Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services